申请人:DANA-FARBER CANCER INSTITUTE, INC.
公开号:US20210355119A1
公开(公告)日:2021-11-18
The application relates to a compound having Formula I which modulates the activity of HER2 and/or a mutant thereof, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which HER2 and/or a mutant thereof plays a role.